DK1414471T3 - Therapeutic agents comprising pro-apoptotic proteins - Google Patents

Therapeutic agents comprising pro-apoptotic proteins

Info

Publication number
DK1414471T3
DK1414471T3 DK02763328.8T DK02763328T DK1414471T3 DK 1414471 T3 DK1414471 T3 DK 1414471T3 DK 02763328 T DK02763328 T DK 02763328T DK 1414471 T3 DK1414471 T3 DK 1414471T3
Authority
DK
Denmark
Prior art keywords
pro
therapeutic agents
apoptotic proteins
apoptotic
proteins
Prior art date
Application number
DK02763328.8T
Other languages
Danish (da)
Inventor
Michael G Rosenblum
Yuying Liu
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of DK1414471T3 publication Critical patent/DK1414471T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
DK02763328.8T 2001-07-17 2002-07-17 Therapeutic agents comprising pro-apoptotic proteins DK1414471T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30609101P 2001-07-17 2001-07-17
US33288601P 2001-11-06 2001-11-06
US36036102P 2002-02-28 2002-02-28
PCT/US2002/023378 WO2003007889A2 (en) 2001-07-17 2002-07-17 Therapeutic agents comprising pro-apoptotic proteins

Publications (1)

Publication Number Publication Date
DK1414471T3 true DK1414471T3 (en) 2012-07-16

Family

ID=27405139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02763328.8T DK1414471T3 (en) 2001-07-17 2002-07-17 Therapeutic agents comprising pro-apoptotic proteins

Country Status (11)

Country Link
US (5) US7101977B2 (en)
EP (1) EP1414471B1 (en)
JP (1) JP2004535202A (en)
KR (1) KR100891272B1 (en)
CN (1) CN1555268B (en)
AU (1) AU2002327310B2 (en)
CA (1) CA2454048C (en)
DK (1) DK1414471T3 (en)
IL (2) IL159894A0 (en)
NZ (1) NZ530582A (en)
WO (1) WO2003007889A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
BR0010017A (en) * 1999-04-28 2002-06-11 Univ Texas Compositions and processes for the treatment of cancer by selective vegf inhibition
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20030186384A1 (en) * 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2003275985A1 (en) * 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
DK1537204T3 (en) * 2002-08-23 2010-06-07 Gabriele Prof Dr Multhoff Granzym B as HSP70 / HSP70 peptide-dependent triggers of programmed cell death in tumor cells
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
CA2527984A1 (en) * 2003-06-05 2004-12-16 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2005068616A2 (en) * 2004-01-16 2005-07-28 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
CN102258503B (en) 2004-01-22 2019-08-16 迈阿密大学 Topical co-enzyme Q 10 formulations and its application method
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US8017747B2 (en) * 2004-08-26 2011-09-13 Nationwide Children's Hospital, Inc. Apoptosis-inducing genes for treating cancer
JP2008526889A (en) * 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション Targeted chimeric molecules for cancer therapy
RU2393874C2 (en) * 2005-02-01 2010-07-10 Рисерч Дивелопмент Фаундейшн Polypeptides of directed action
RU2007139283A (en) * 2005-03-25 2009-04-27 Гликарт Биотехнологи Аг (Ch) ANTI-BINDING MOLECULES DIRECTED TO MCSP AND HAVING AN INCREASED BINDING OF Fc-RECEPTOR AND EFFECTOR FUNCTION
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
KR20080041145A (en) * 2005-04-12 2008-05-09 인트라디그엠 코오포레이션 Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
SI1940457T1 (en) * 2005-10-21 2013-04-30 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP1800695A1 (en) * 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
WO2007144882A2 (en) * 2006-06-14 2007-12-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted chimeric proteins
WO2008011157A2 (en) 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US20100183516A1 (en) * 2007-07-25 2010-07-22 Markus Ribbert Self coupling recombinant antibody fusion proteins
WO2009081854A1 (en) * 2007-12-21 2009-07-02 University Of Toyama Biomarker for allergic disease and utilization of the same
JP6058263B2 (en) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー Methods and uses for inducing apoptosis in cancer cells
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
RU2498819C2 (en) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Pharmaceutical composition for treating and preventing malignant growths
DK2325648T3 (en) 2008-08-05 2014-07-28 Toray Industries METHOD OF DETECTING CANCER
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010075194A1 (en) * 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active dkk
US20110020312A1 (en) 2009-05-11 2011-01-27 Niven Rajin Narain Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
FR2949787A1 (en) * 2009-09-09 2011-03-11 Centre Nat Rech Scient MOLECULES CAPABLE OF PERFORATING MITOCHONDRIA AND THEIR APPLICATIONS
WO2011048589A2 (en) * 2009-10-23 2011-04-28 Ben Gurion University Of The Negev Research And Development Authority Ion exchangers and methods of use thereof
MX2012008656A (en) * 2010-01-25 2012-08-23 Abbott Lab Rapid characterization of proteins in complex biological fluids.
EP2619313B1 (en) 2010-09-26 2021-11-10 Da Yu Enterprises, L.L.C. Method of recombinant macromolecular production
CN103608323B (en) 2011-04-04 2016-08-17 博格有限责任公司 The method for the treatment of central nerve neuroma
PT2741085T (en) 2011-08-04 2017-06-30 Toray Industries Method for detecting pancreatic cancer
JP2015502340A (en) 2011-10-27 2015-01-22 エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Humanized antibody against iNKT
KR102005786B1 (en) 2012-02-21 2019-07-31 도레이 카부시키가이샤 Medicinal composition for treating and/or preventing cancer
EP2811034A4 (en) * 2012-03-14 2015-11-11 Lsip Llc Method for screening anticancer drugs, and anticancer drug that induces cell death and uses substance that increases granzyme m activity as active ingredient
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
CN104471403B (en) 2012-07-19 2017-03-01 东丽株式会社 The detection method of cancer
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies
EP2730289A1 (en) * 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
EP2945645B8 (en) * 2013-01-17 2019-10-23 Sylvain Tourel Selective cell-death-inducing binary enzyme system
AU2014251045B2 (en) 2013-04-08 2019-06-13 Berg Llc Treatment of cancer using coenzyme Q10 combination therapies
MX360671B (en) 2013-08-09 2018-11-13 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
SG11201601583TA (en) 2013-09-04 2016-04-28 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
KR102488961B1 (en) * 2014-05-19 2023-01-16 삼성전자주식회사 Fusion protein comprising Granzyme B and use thereof
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
WO2017209274A1 (en) * 2016-06-02 2017-12-07 国立研究開発法人理化学研究所 Adjuvant composition and use thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20200330581A1 (en) * 2017-10-09 2020-10-22 Keith Black Oncolytic cancer immunotherapies and methods of use
WO2020219504A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
CN115477705B (en) * 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on granzyme B
WO2024117543A1 (en) * 2022-11-29 2024-06-06 주식회사 신렉스 Cancer cell-specific gene expression system

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4522918A (en) 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0118365B1 (en) 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
FR2546756B1 (en) 1983-06-03 1985-11-29 Centre Nat Rech Scient NOVEL IMMUNOSTIMULATING DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666845A (en) 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
DE3586216T2 (en) 1984-05-01 1992-12-10 Ciba Corning Diagnostics Corp BREAST TUMOR ASSOCIATED ANTIQUE AND MONOCLONAL ANTIBODIES THEREFOR.
FR2566271B1 (en) 1984-06-20 1986-11-07 Sanofi Sa NOVEL CYTOTOXIC CONJUGATES FOR USE IN THERAPEUTICS AND PROCESS FOR OBTAINING SAME
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
DE3585778D1 (en) 1984-12-05 1992-05-07 Salk Inst For Biological Studi MONOCLONAL ANTIBODY, SPECIFIC FOR BREAST CANCER CELL SURFACE ANTIQUE.
US5032521A (en) 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
CA1339798C (en) 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
EP0214995B1 (en) 1985-03-04 1990-12-27 Dana Farber Cancer Institute Immunotoxin and method of making
US4888415A (en) 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
JP2524586B2 (en) 1985-06-26 1996-08-14 シタス コーポレイション Solubilization of proteins for pharmaceutical compositions utilizing polymer conjugation
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3685485D1 (en) 1985-12-06 1992-07-02 Cetus Corp ANTI-IMMUNTOXINE AGAINST HUMAN OVARY CANCER AND METHOD FOR USE THEREOF.
US4962188A (en) 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4831122A (en) 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
JPS62190200A (en) 1986-02-17 1987-08-20 Res Dev Corp Of Japan Anti-tumor protein complex and production thereof
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US4894225A (en) 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
NO881077L (en) 1987-03-11 1988-09-12 Univ Michigan Chemo-RADIO IMMUNO conjugates.
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5095096A (en) 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
US4863726A (en) 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0305967B1 (en) 1987-09-02 1993-05-05 Ciba-Geigy Ag Conjugates of interferon alpha with immunoglobulins
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5099842A (en) * 1988-10-28 1992-03-31 Nellcor Incorporated Perinatal pulse oximetry probe
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
IE62496B1 (en) 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US6306626B1 (en) 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DE69123241T2 (en) 1990-12-14 1997-04-17 Cell Genesys Inc CHIMERIC CHAINS FOR TRANSDUCTING RECEPTOR-RELATED SIGNAL PATHS
RU2142015C1 (en) 1991-09-06 1999-11-27 Рисерч Дивелопмент Фаундейшн Dna fragment encoding protein gelonin and method of its producing, vector providing protein gelonin expression, recombinant strain escherichia coli - producer of protein gelonin
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
CA2162689C (en) 1993-05-12 2000-07-18 Marc D. Better Immunotoxins comprising gelonin and an antibody
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5942230A (en) 1994-05-06 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Composition of immunotoxins and retinoids and use thereof
US5513296A (en) * 1994-06-08 1996-04-30 Holmes Products Corp. Air heater with angled PTC heaters producing diverging heated airflow
JP3033068B2 (en) 1994-06-20 2000-04-17 富士写真光機株式会社 Film feed control device
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
US5851815A (en) 1996-03-19 1998-12-22 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic proteases
IL118570A (en) 1996-06-04 2007-06-17 Shai Yarkoni USE OF A CHIMERIC PROTEIN COMPRISING Met-GnRH IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING ADENOCARCINOMA OR HEPATOCARCINOMA
NZ338013A (en) * 1997-02-28 2001-05-25 Boehringer Ingelheim Pharma Use of TNFp-AIG (containing selected native elements of TNF-alpha promoter) for treating inflammatory diseases, such as rheumatoid arthritis
EP0893493A3 (en) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetically modified cells and their use for prophylaxis or treatment of diseases
ATE294865T1 (en) 1998-02-04 2005-05-15 Thromb X N V IDENTIFICATION, PRODUCTION AND USE OF STAPHYLOKINASE DERIVATIVES WITH REDUCED IMMUNOGENICITY AND/OR REDUCED CLEARANCE
KR20010086587A (en) * 1998-02-27 2001-09-13 데이비드 이. 프랭크하우저 Self-regulated apoptosis of inflammatory cells by gene therapy
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6140066A (en) 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
WO1999051620A1 (en) 1998-04-03 1999-10-14 Invitrogen Corporation Libraries of expressible gene sequences
US20040009477A1 (en) 1998-04-03 2004-01-15 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
AU754276B2 (en) 1998-04-03 2002-11-07 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CU22732A1 (en) 1998-08-14 2002-02-28 Ct Ingenieria Genetica Biotech MUTANTS OF STREPTOQUINASE
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU2631501A (en) 2000-01-06 2001-07-16 Monsanto Technology Llc Preparation of deallergenized proteins and permuteins
US20030186384A1 (en) 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
GB0116047D0 (en) 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2003275985A1 (en) 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof

Also Published As

Publication number Publication date
US20030086919A1 (en) 2003-05-08
EP1414471B1 (en) 2012-06-13
US7101977B2 (en) 2006-09-05
US20120252097A1 (en) 2012-10-04
EP1414471A2 (en) 2004-05-06
US20110002910A1 (en) 2011-01-06
NZ530582A (en) 2008-06-30
KR100891272B1 (en) 2009-04-06
EP1414471A4 (en) 2005-12-28
IL159894A0 (en) 2004-06-20
CA2454048A1 (en) 2003-01-30
CN1555268B (en) 2013-04-03
WO2003007889A2 (en) 2003-01-30
IL159894A (en) 2010-05-17
JP2004535202A (en) 2004-11-25
US20060280749A1 (en) 2006-12-14
US20090010917A1 (en) 2009-01-08
US8043831B2 (en) 2011-10-25
US8530225B2 (en) 2013-09-10
CA2454048C (en) 2011-05-03
US7371723B2 (en) 2008-05-13
US7759091B2 (en) 2010-07-20
CN1555268A (en) 2004-12-15
WO2003007889A3 (en) 2003-10-09
KR20040038982A (en) 2004-05-08
AU2002327310B2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DK1414471T3 (en) Therapeutic agents comprising pro-apoptotic proteins
NO20040402L (en) Peptide-based multimeric targeting agents
NO20033556D0 (en) Pharmaceutical preparations
NO20033549D0 (en) Therapeutic bonding molecules
DE60210864D1 (en) Modified fluorescent protein
DE60226425D1 (en) SOLUBLE RAGE PROTEIN
NO20034097L (en) Hormone Replacement Therapy
NO20035315D0 (en) Pharmaceutical combinations
DE60208982D1 (en) footbath
DE50200615D1 (en) gemini
NO20035224D0 (en) Ophthalmic pirenzepel
DE50209245D1 (en) NEUROPROTEKTIVES MEDICAMENT
DE50200250D1 (en) gemini
NO20014597D0 (en) Approach
DE60114244D1 (en) osteosynthesis
NO20032963D0 (en) peptide
ATA5002002A (en) VIBRATOR
DE60237655D1 (en) processor
ZA200400228B (en) Therapeutic agents comprising pro-apoptotic proteins
DE60117001D1 (en) NECTIN-3 PROTEINS
DE10157913B4 (en) therapy table
NO20020794D0 (en) Me-1 protein
SE0103854D0 (en) Therapeutic agents
SE0103855D0 (en) Therapeutic agents
SE0104413D0 (en) New protein